H1N1ワクチン市場：投与経路、ブランドタイプ、流通チャネル別-2025-2030年の世界予測

H1N1ワクチン市場は、2023年に99億3,000万米ドルと評価され、2024年には134億5,000万米ドルに達すると予想され、CAGR 35.51％で成長し、2030年には833億9,000万米ドルに達すると予測されています。

H1N1ワクチン市場の範囲と定義は、一般に豚インフルエンザとして知られるH1N1インフルエンザウイルスに対抗することを目的としたワクチンの開発、生産、流通を中心に展開されます。これらのワクチンの必要性は、広範な病気や死亡につながるインフルエンザの流行がもたらす世界の健康リスクに起因しています。主な用途としては、ヘルスケア従事者、小児、高齢者、免疫力の低下した人々など、リスクの高い人々を対象とした予防接種が挙げられます。最終用途は、公衆衛生活動、病院や臨床現場、政府の備蓄戦略など多岐にわたる。市場成長の原動力となっているのは、感染症予防に対する意識の高まり、ワクチン技術の進歩、政府の保健政策支援といった要因です。最近の市場動向では、新興国市場での拡大、迅速なワクチン開拓のためのmRNA技術の活用、遠隔地におけるワクチンの安定性と到達性を確保するためのコールドチェーン・ロジスティクスの強化に潜在的な機会があることが強調されています。このような機会を捉えるための調査には、次世代ワクチンのための高度な研究開発（R&D）への投資、広範な流通ネットワークのための戦略的パートナーシップの構築、保健インフラを強化するための官民協力への関与などが含まれます。

しかし、ワクチンの承認を遅らせる規制上のハードル、世界の流通における政治的・物流的課題、誤った情報によって増幅される一般市民のワクチンへのためらいなどの制約があります。これらの課題に対処するためには、ワクチンの安全性と有効性に関する継続的な教育努力と透明性のあるコミュニケーションが必要です。技術革新の可能性のある最良の分野は、普遍的なインフルエンザワクチンの開発、ワクチンの保管・配送システムの強化、ワクチン配布の追跡・管理を改善するためのデジタルヘルス技術の統合です。この市場の性質を考察すると、公衆衛生上の緊急ニーズへの対応と将来の流行予測という2つの要請によって、非常に競合が激しく、急速に進化していることがわかる。この市場への参入を成功させるには、戦略的な先見性と、ワクチン市場特有の複雑な状況を乗り切る敏捷性が必要です。

市場力学：急速に進化するH1N1ワクチン市場の主要市場インサイトを公開

H1N1ワクチン市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 新型インフルエンザ感染の増加
  • 妊婦や小児における不活化インフルエンザワクチンの需要
  • 細胞ベース製造へのシフト
• 市場抑制要因
  • 製造工程に時間がかかり、コストが高い
• 市場機会
  • コスト効率に優れた供給のための官民パートナーシップ
  • ワクチンの技術的進歩
• 市場の課題
  • H1N1ワクチンに関連する一般的な副作用

ポーターの5つの力：H1N1ワクチン市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：H1N1ワクチン市場における外部からの影響の把握

外部マクロ環境要因は、H1N1ワクチン市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析H1N1ワクチン市場における競合情勢の把握

H1N1ワクチン市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスH1N1ワクチン市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、H1N1ワクチン市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨H1N1ワクチン市場における成功への道筋を描く

H1N1ワクチン市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 流行性H1N1感染症の発生率上昇
    • 妊婦と小児における不活化インフルエンザワクチンの需要
    • 細胞ベースの製造への移行
  • 抑制要因
    • 製造プロセスに時間がかかり、コストも高い
  • 機会
    • コスト効率の高い供給のための官民パートナーシップ
    • ワクチンの技術的進歩
  • 課題
    • H1N1ワクチンに関連する一般的な副作用
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 H1N1ワクチン市場：投与経路別

• 皮内ワクチン
• 筋肉内ワクチン
• 鼻腔内ワクチン

第7章 H1N1ワクチン市場ブランド別

• アグリパル
• フィアリックス
• インフルゲン
• インフルバック
• ナソヴァツ
• ヴァクシグリップ

第8章 H1N1ワクチン市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第9章 南北アメリカのH1N1ワクチン市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のH1N1ワクチン市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのH1N1ワクチン市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Baxter International Inc.
• Cipla Limited
• Cochin Shipyard Ltd.
• Glaxo Smith Kline
• Hualan Biological Engineering Inc.
• MedImmune, LLC
• Merck KGaA
• Mitsubishi Tanabe Pharma Corporation
• Pfizer Inc.
• Sanofi S.A.
• Sinovac Biotech Ltd.

LIST OF FIGURES

• FIGURE 1. H1N1 VACCINES MARKET RESEARCH PROCESS
• FIGURE 2. H1N1 VACCINES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL H1N1 VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL H1N1 VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES H1N1 VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES H1N1 VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. H1N1 VACCINES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. H1N1 VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. H1N1 VACCINES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL H1N1 VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL H1N1 VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. H1N1 VACCINES MARKET DYNAMICS
• TABLE 7. GLOBAL H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL H1N1 VACCINES MARKET SIZE, BY INTRADERMAL VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL H1N1 VACCINES MARKET SIZE, BY INTRAMUSCULAR VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL H1N1 VACCINES MARKET SIZE, BY INTRANASAL VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL H1N1 VACCINES MARKET SIZE, BY AGRIPAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL H1N1 VACCINES MARKET SIZE, BY FIUARIX, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL H1N1 VACCINES MARKET SIZE, BY INFLUGEN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL H1N1 VACCINES MARKET SIZE, BY INFLUVAC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL H1N1 VACCINES MARKET SIZE, BY NASOVAC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL H1N1 VACCINES MARKET SIZE, BY VAXIGRIP, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL H1N1 VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL H1N1 VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL H1N1 VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 32. CANADA H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 33. CANADA H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 34. CANADA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES H1N1 VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 48. AUSTRALIA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. CHINA H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 50. CHINA H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 51. CHINA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. INDIA H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 53. INDIA H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 54. INDIA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 57. INDONESIA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 60. JAPAN H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 63. MALAYSIA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 66. PHILIPPINES H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 69. SINGAPORE H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 72. SOUTH KOREA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 75. TAIWAN H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 78. THAILAND H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 81. VIETNAM H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA H1N1 VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 88. DENMARK H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 91. EGYPT H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 94. FINLAND H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 97. FRANCE H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 100. GERMANY H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 103. ISRAEL H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 104. ITALY H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 105. ITALY H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 106. ITALY H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 109. NETHERLANDS H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 112. NIGERIA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 115. NORWAY H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. POLAND H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 117. POLAND H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 118. POLAND H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 119. QATAR H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 120. QATAR H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 121. QATAR H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 124. RUSSIA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 127. SAUDI ARABIA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH AFRICA H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 133. SPAIN H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 136. SWEDEN H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 139. SWITZERLAND H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 142. TURKEY H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 145. UNITED ARAB EMIRATES H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM H1N1 VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM H1N1 VACCINES MARKET SIZE, BY TYPE OF BRAND, 2018-2030 (USD MILLION)
• TABLE 148. UNITED KINGDOM H1N1 VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 149. H1N1 VACCINES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 150. H1N1 VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

The H1N1 Vaccines Market was valued at USD 9.93 billion in 2023, expected to reach USD 13.45 billion in 2024, and is projected to grow at a CAGR of 35.51%, to USD 83.39 billion by 2030.

The H1N1 vaccine market scope and definition revolve around the development, production, and distribution of vaccines aimed at combating the H1N1 influenza virus, commonly known as swine flu. The necessity for these vaccines stems from the global health risk presented by flu outbreaks, which can lead to widespread illness and mortality. Applications primarily include immunization efforts targeting high-risk populations such as healthcare workers, children, the elderly, and those with compromised immune systems. End-use scope spans public health initiatives, hospital and clinical settings, and government stockpiling strategies. Market growth is driven by factors such as increasing awareness of infectious disease prevention, advancements in vaccine technology, and supportive governmental health policies. Recent market dynamics highlight potential opportunities in the expansion within emerging markets, leveraging mRNA technology for rapid vaccine development, and enhancing cold chain logistics to ensure vaccine stability and reach in remote areas. Recommendations to seize these opportunities include investing in advanced research and development (R&D) for next-generation vaccines, forging strategic partnerships for broad distribution networks, and engaging in public-private collaborations to enhance health infrastructure.

However, limitations include regulatory hurdles that can delay vaccine approval, political and logistical challenges in global distribution, and public vaccine hesitancy amplified by misinformation. Addressing these challenges calls for continuous education efforts and transparent communication about vaccine safety and efficacy. The best possible areas of innovation involve developing universal flu vaccines, enhancing vaccine storage and delivery systems, and integrating digital health technologies for better tracking and managing vaccine distribution. Insight into the nature of this market reveals it to be highly competitive and rapidly evolving, driven by the dual imperatives of addressing immediate public health needs and anticipating future outbreaks. Successful engagement requires strategic foresight and agility to navigate the complexities inherent in the vaccine landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving H1N1 Vaccines Market

The H1N1 Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidences of epidemic H1N1 infection
  • Demand for inactivated influenza vaccine in pregnant women and children
  • Shift towards cell-based manufacturing
• Market Restraints
  • Time consuming manufacturing process and high cost
• Market Opportunities
  • Public-private partnerships for cost effective supply
  • Technological advancements in the vaccines
• Market Challenges
  • Common side effects associated with H1N1 vaccines

Porter's Five Forces: A Strategic Tool for Navigating the H1N1 Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the H1N1 Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the H1N1 Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the H1N1 Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the H1N1 Vaccines Market

A detailed market share analysis in the H1N1 Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the H1N1 Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the H1N1 Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the H1N1 Vaccines Market

A strategic analysis of the H1N1 Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the H1N1 Vaccines Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Baxter International Inc., Cipla Limited, Cochin Shipyard Ltd., Glaxo Smith Kline, Hualan Biological Engineering Inc., MedImmune, LLC, Merck KGaA, Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., Sanofi S.A., and Sinovac Biotech Ltd..

Market Segmentation & Coverage

This research report categorizes the H1N1 Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Route of Administration, market is studied across Intradermal Vaccines, Intramuscular Vaccines, and Intranasal Vaccines.
• Based on Type of Brand, market is studied across Agripal, Fiuarix, Influgen, Influvac, Nasovac, and Vaxigrip.
• Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidences of epidemic H1N1 infection
    • 5.1.1.2. Demand for inactivated influenza vaccine in pregnant women and children
    • 5.1.1.3. Shift towards cell-based manufacturing
  • 5.1.2. Restraints
    • 5.1.2.1. Time consuming manufacturing process and high cost
  • 5.1.3. Opportunities
    • 5.1.3.1. Public-private partnerships for cost effective supply
    • 5.1.3.2. Technological advancements in the vaccines
  • 5.1.4. Challenges
    • 5.1.4.1. Common side effects associated with H1N1 vaccines
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. H1N1 Vaccines Market, by Route of Administration

• 6.1. Introduction
• 6.2. Intradermal Vaccines
• 6.3. Intramuscular Vaccines
• 6.4. Intranasal Vaccines

7. H1N1 Vaccines Market, by Type of Brand

• 7.1. Introduction
• 7.2. Agripal
• 7.3. Fiuarix
• 7.4. Influgen
• 7.5. Influvac
• 7.6. Nasovac
• 7.7. Vaxigrip

8. H1N1 Vaccines Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacy
• 8.3. Online Pharmacy
• 8.4. Retail Pharmacy

9. Americas H1N1 Vaccines Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific H1N1 Vaccines Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa H1N1 Vaccines Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Baxter International Inc.
• 3. Cipla Limited
• 4. Cochin Shipyard Ltd.
• 5. Glaxo Smith Kline
• 6. Hualan Biological Engineering Inc.
• 7. MedImmune, LLC
• 8. Merck KGaA
• 9. Mitsubishi Tanabe Pharma Corporation
• 10. Pfizer Inc.
• 11. Sanofi S.A.
• 12. Sinovac Biotech Ltd.